Literature DB >> 17659971

Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.

Wico W Lai1, Kai On Chu, Kwok Ping Chan, Kwong Wai Choy, Chi Chiu Wang, Chi Wai Tsang, Chi Pui Pang.   

Abstract

PURPOSE: To investigate the penetration of ofloxacin and moxifloxacin into the aqueous and vitreous after topical administration one hour before vitrectomy surgery.
DESIGN: Prospective, randomized, double-blind case series study.
METHODS: Twenty-seven patients undergoing vitrectomy were randomized to receive either topical ofloxacin 0.3% or moxifloxacin 0.5% every 10 minutes for one hour before surgery. Aqueous and vitreous samples were obtained and analyzed using high-performance liquidation chromatography.
RESULTS: The moxifloxacin aqueous (1.576 +/- 0.745 microg/ml) and vitreous (0.225 +/- 0.013 microg/ml) levels were significantly higher than the ofloxacin aqueous (0.816 +/- 0.504 microg/ml) (P = .0009) and vitreous (0.225 +/- 0.013 microg/ml) [P = .0054] levels, respectively. The mean moxifloxacin aqueous and vitreous levels exceeded the minimum inhibitory concentration for 90% of isolates (MIC(90)) for a wide variety of bacteria implicated in endophthalmitis. In contrast, the aqueous level of ofloxacin exceeded the MIC(90) of only a few organisms.
CONCLUSIONS: Moxifloxacin applied every 10 minutes during the hour before vitrectomy penetrated the eye significantly better than ofloxacin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659971     DOI: 10.1016/j.ajo.2007.03.036

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Safety of prophylactic intracameral moxifloxacin ophthalmic solution after cataract surgery in patients with penetrating keratoplasty.

Authors:  Osman Sevki Arslan; Ceyhun Arici; Mustafa Unal; Erdogan Cicik; Mehmet Serhat Mangan; Eray Atalay
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

2.  Severe bacterial endophthalmitis: towards improving clinical outcomes.

Authors:  Billy D Novosad; Michelle C Callegan
Journal:  Expert Rev Ophthalmol       Date:  2010-10

3.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 4.  Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

5.  Assessment of vitreous drug concentration in the porcine eye following intracameral injection or irrigation with moxifloxacin.

Authors:  Kazuki Matsuura; Yoshitsugu Inoue; Shin-Ichi Sasaki; Yoshio Hata; Nami Ohmura; Takahiro Gotou
Journal:  Clin Ophthalmol       Date:  2013-07-09

6.  Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery.

Authors:  Frank A Bucci; Ines Teuma Nguimfack; Angel T Fluet
Journal:  Clin Ophthalmol       Date:  2016-05-02

7.  Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes.

Authors:  G C M Silva; V A P Jabor; P S Bonato; E Z Martinez; S J Faria-E-Sousa
Journal:  Braz J Med Biol Res       Date:  2017-07-03       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.